4-cyclopropylmethyloxyphenylacetic acid | 1046140-47-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-cyclopropylmethyloxyphenylacetic acid
• 英文别名: 2-[4-(cyclopropylmethoxy)phenyl]acetic acid；[4-(cyclopropylmethoxy)phenyl]acetic acid；(4-Cyclopropylmethoxy-phenyl)-acetic acid
• CAS: 1046140-47-9
• 化学式: C₁₂H₁₄O₃
• 分子量: 206.241
• InChiKey: PDFXHMGRUAHEGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-cyclopropylmethyloxyphenylacetic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 乙酸酐 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 methyl-3-(E)-(4-(3-(cyclopropylamino)-2-(4-fluorophenyl)-3-oxoprop-1-en-1-yl)phenyl)acrylate
  参考文献：
  名称：

  Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts

  摘要：

  Herein we report the synthesis and activity of a novel class of HDAC inhibitors based on 2, 3-diphenyl acrylic acid derivatives. The compounds in this series have shown to be potent HDAC inhibitors possessing significant antiproliferative activity. Further compounds in this series were subjected to metabolic stability in human liver microsomes (HLM), mouse liver microsomes (MLM), and exhibits promising stability in both. These efforts culminated with the identification of a developmental candidate (5a), which displayed desirable PK/PD relationships, significant efficacy in the xenograft models and attractive ADME profiles. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.11.014
• 作为产物：
  描述：

  methyl 2-[4-(cyclopropylmethoxy)phenyl]acetate 在 lithium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 4-cyclopropylmethyloxyphenylacetic acid
  参考文献：
  名称：

  Novel benzimidazole derivatives as selective CB2 agonists

  摘要：

  The preparation and evaluation of a novel class of CB2 agonists based on a benzimidazole moiety are reported. They showed binding affinities up to 1 nM towards the CB2 receptor with partial to full agonist potencies. They also demonstrated good to excellent selectivity (> 1000-fold) over the CB1 receptor. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.05.073

文献信息

• COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS
  申请人：Tang Pingwah

  公开号：US20100074861A1

  公开（公告）日：2010-03-25

  Compounds comprising cyclic moiety and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.

  本发明提供了由环状基团组成的化合物和用于传递活性剂的组合物。同时也提供了其管理和制备方法。
• [EN] COMPOUNDS, SALTS THEREOF AND THEIR USE IN THE TREATMENT OF DISEASES<br/>[FR] COMPOSÉS, SELS ASSOCIÉS ET MÉTHODES POUR LE TRAITEMENT DE MALADIES
  申请人：ACADIA PHARM INC

  公开号：WO2019040106A3

  公开（公告）日：2019-04-18
• COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE
  申请人：Urigen Pharmaceuticals, Inc.

  公开号：EP3110427A1

  公开（公告）日：2017-01-04
• COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS
  申请人：PARSONS C. Lowell

  公开号：US20170189443A1

  公开（公告）日：2017-07-06

  The present invention is directed to a pharmaceutical composition comprising: (1) a therapeutically effective quantity of sodium pentosan polysulfate; (2) a quantity of a penetration enhancer sufficient to improve the bioavailability of the sodium pentosan polysulfate; and (3) optionally, a pharmaceutically acceptable carrier and to methods for the oral administration of sodium pentosan polysulfate with improved bioavailability for the treatment of interstitial cystitis and other urinary tract diseases and conditions. Such compositions and methods allow the administration of sodium pentosan polysulfate at lower dosages to reduce the frequency and severity of side effects.
• US8383852B2
  申请人：——

  公开号：US8383852B2

  公开（公告）日：2013-02-26